SecBot SecBot

CMMB drug pipeline

$1.62
+5.9% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 mixed
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 2 (complete); preparing Phase 3
Time to marketAt least 4-6 years; Phase 3 PSC trial not yet initiated, and even if successful, filing and approval would follow several years later. The new RA program is even earlier-stage.

nebokitug Updated Jul 8

What to watch

The just-announced merger with Scipher Medicine (all-stock, closing Q4 2026) reshapes the investment thesis: pre-merger Chemomab holders get ~32% of the combined entity plus CVRs tied to nebokitug milestones, while the new company will run an AI-guided Phase 2 RA trial. Watch for Phase 3 PSC trial financing clarity post-merger and the merger close vote. The stock already ran ~80% into the deal, much of the near-term re-rating may be priced in.

Bull case
  • PSC is a rare liver disease with ZERO FDA-approved disease-modifying therapies, nebokitug could be first-to-market if Phase 3 succeeds, addressing a high-unmet-need orphan population.
  • Phase 2 SPRING trial showed dose-dependent improvements across fibrotic, inflammatory, and cholestatic biomarkers; results published in the American Journal of Gastroenterology, lending credibility.
  • FDA and EMA both granted Orphan Drug designation; FDA also gave Fast Track status; FDA agreed to a single pivotal Phase 3 trial design without liver biopsy, lowering the regulatory bar.
Bear case
  • Phase 3 PSC trial has NOT started, it remains contingent on financing. The merger gives $30M but Scipher shareholders get ~68% of the combined entity, massively diluting pre-merger CMMB holders.
  • The stock closed at $2.13 on merger announcement day, down ~54% from the prior close of $4.64, suggesting the market interpreted the deal terms as unfavorable for Chemomab shareholders.
  • Nebokitug is Chemomab's only asset, single-drug binary risk. A Phase 3 failure would leave the company with virtually nothing.

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
nebokitugCM-101 in PSC Patients -The SPRING StudyPhase 2Completed · results77Jan 10, 2025